ReviewClinical genetics2012
Epigenetic modifications in cancer.
Review in Clinical genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 264 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
264 citing papers in PubMed, 2 syntheses or guidelines pooled it, 527 citations in OpenAlex.
- Epigenetic reprogramming and antitumor immune responses in gliomas: a systematic review.Medical oncology (Northwood, London, England) · 2025Pooled it
- Guidelines for pre-analytical conditions for assessing the methylation of circulating cell-free DNA.Clinical epigenetics · 2021Pooled it
- DNA methylation-mediated regulation of TRAIL pathway components (DR5, DcR2, and CASP3) in breast cancer: molecular mechanisms and therapeutic implications.Molecular biology reports · 2026Review
- Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.Oncogene · 2026Article
- Transcriptomic and epigenomic insights into ovarian cancer: a bioinformatics perspective - a narrative review.Annals of medicine and surgery (2012) · 2026Article
- PKM2 Deficiency Results in Reduced Proliferation of Nasopharyngeal Carcinoma Cells by Deactivation of Nrf2-HO-1-GSH Signaling.Applied biochemistry and biotechnology · 2026Article
- Advances in multi-omics for esophageal squamous cell carcinoma: diagnostic, prognostic, and therapeutic perspectives.Protein & cell · 2026Review
- Amino Acids as Targets for Immunotherapy against Solid Tumors.Cell biochemistry and biophysics · 2026Review
- Catching pancreatic cancer early: Are we there yet?Journal of the National Cancer Center · 2026Review
- The Future of Epigenetics: Emerging Technologies and Clinical Applications.ACS pharmacology & translational science · 2026Review
- Epigenetic modulation to overcome immune suppression in pancreatic cancer.Clinical epigenetics · 2026Review
- Rare KDM4C variants and reduced expression underlie epigenetic dysregulation in rheumatoid arthritis.Immunologic research · 2026Article
- Review
- Censorship in science: How publishing decisions could have shaped the perceived "general consensus" on COVID-19 vaccine safety and efficacy.Oncotarget · 2026Article
- Differences in MicroRNA Expression in Firefighters Responding to a Train Derailment and Fire in East Palestine, Ohio.Epigenomes · 2026Article
- Expression Levels of DNMT1, HDAC1, and MT1E Genes as Diagnostic Biomarkers for Breast Cancer Clinicopathological Features: In Vitro and In Silico Analyses.Analytical cellular pathology (Amsterdam) · 2026Article
- Advancements in cancer biomarker discovery over fifteen years: diagnostics and prognostic approach in somatic cancer.Oncology reviews · 2026Review
- A Comprehensive Review of Nanotechnological Innovations in Cancer: from Molecular Pathways to Clinical Applications.Journal of Cancer · 2026Review
- Integrative omics approaches to uncover liquid-based cancer-predicting biomarkers in Lynch syndrome.International journal of cancer · 2026Article
- Nutritional approaches in combating therapeutic resistance and enhancing treatment efficacy in cancer: the impact of ketogenic diets.Nutrition & metabolism · 2025Review
204 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cancer initiation and progression is controlled by both genetic and epigenetic events. The complexity of carcinogenesis cannot be accounted for by genetic alterations alone but also involves epigenetic changes. Epigenetics refers to the study of mechanisms that alter gene expression without altering the primary DNA sequence. Epigenetic mechanisms are heritable and reversible, and include changes in DNA methylation, histone modifications and small noncoding microRNAs (miRNA). Disruption of epigenetic processes can lead to altered gene function and malignant cellular transformation. Aberrant epigenetic modifications probably occur at a very early stage in neoplastic development, and they are widely described as essential players in cancer progression. Recent advances in epigenetics offer a better understanding of the underlying mechanism(s) of carcinogenesis and provide insight into the discovery of putative cancer biomarkers for early detection, disease monitoring, prognosis, and risk assessment. In this review, we summarize the current literature on epigenetic changes causing genetic alterations that are thought to contribute to cancer, and discuss the potential impact of epigenetics future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.